peptide for weight loss retatrutide 🎙️ NEW EPISODE: Retatrutide—The Triple Agonist Not licensed Will this replace the current GLP-1 in the market., This triple receptor agonist (GIP/GLP-1/glucagon) is showing unprecedented results in retatrutide peptide muscle growth OUR

Description

doi: 10.1210/jendso/bvab048.013 Formichi C, Fignani D, Nigi L, et al

Compounded products are exempt from FDA approval and no claims are made to the safety and efficacy of any compounded product for any indication or specific use

How GLP-1 Medications Are Processed in the Body GLP-1 receptor agonists undergo hepatic metabolism and renal clearance

Kannel WB, Wilson PW (1995) Risk factors that attenuate the female coronary disease advantage

It's an investigational drug currently in Phase 3 clinical trials Eli Lilly's TRIUMPH Phase 3 program includes multiple trials for obesity, type 2 diabetes, NASH, and cardiovascular outcomes Expected timeline: FDA submission in 2026, potential approval in 20272028 Phase 2 results showed 24.2% weight loss at 48 weeks, the highest ever recorded for a GLP-1 class medication How to access now: Clinical trial enrollment (free), compounding pharmacies (with important legal caveats), or research peptides (grey market) When approved, retatrutide will be the first triple-agonist obesity medication (GLP-1 + GIP + glucagon) Is Retatrutide FDA Approved